Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure

Clinical Breast Cancer

Volumn 5, Issue 5, 2004, Pages 353-357

  Martin, Miguel ^a   García Donas, Jesus ^a   Casado, Antonio ^a   de la Gándara, Isabel ^b   Pérez Segura, Pedro ^a   García Saenz, Jose Angel ^a   Ibáãnez, Gabriel ^a   Loboff, Belen ^a   García Ledo, Gemma ^a   Moreno, Fernando ^a   Grande, Enrique ^a   Diaz Rubio, Eduardo ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Hospital Nuestra Senora de America   (Spain)

Author keywords

Cardiac toxicity; Hand foot syndrome; Left ventricular ejection fraction; Metastatic disease

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; LIPOSOME; MACROGOL; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; SEPSIS; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 19944426799     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.n.041     Document Type: Article

References (13)

1. Gabizon A, Martin F. Polyethilene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997; 54(suppl 4):15-21.
2. Ranson MR, Carmichael J, O'Byrne K, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. J Clin Oncol 1997; 15:3185-3191.
3. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (CAELYX™/Doxyl) vs.doxoribicin for first-line treatment of metastatic breast cancer. Cancer 2000; 89:1037-1047.
4. Overmoyer B, Silverman P Holder L, et al. Doxil and intravenous cyclophosphamide as first-line therapy for patients with metastatic breast cancer (MBC): interim results of an ongoing pilot trial. Breast Cancer Res Treat 1998; 50:324.
5. Jones V, Finucane D, Rodriguez R, et al. Phase II study of weekly paclitaxel (Taxol) and liposomal doxorubicin (Doxil) in patients with locally advanced breast cancer. Proc Am Soc Clin Oncol 2000; 21:113a (Abstract #451).
6. Gogas H, Papadimitriou C, Kalofonos HP, et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx®) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 2002; 13:1737-1742.
7. Sparano JA, Malik U, Rajdev L, et al. Phase I trial of pegylated lipososmal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 2001; 19:3117-3125.
8. Rivera E, Valero V, Arun B, et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 2003; 21:3249-3254.
9. Burstein HJ, Ramirez MJ, Petros WP, et al. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol 1999; 10:1113-1116.
10. Rimasa L, Carnaghi C, Garassino I, et al. Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 2003; 77:185-188.
11. Gebbia V, Mauceri G, Fallica G, et al. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. Oncology 2002; 63:31-37.
12. Smith GA. Current status of vinorelbine for breast cancer. Oncology 1995; 9:767-773.
13. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13:346-353.